One in eight American adults now takes GLP-1 drugs like Ozempic or Wegovy to lose weight. That shift is rattling food companies, forcing them to rethink how they sell snacks and meals.

Changing appetites, shrinking meals

GLP-1 drugs are rewriting the rules of eating in America. These medications slow digestion, curb appetite, and make people feel full faster. The result? Users often eat less, sometimes cutting their calorie intake by more than 20%. That’s a big hit for food and beverage companies used to selling larger portions and indulgent snacks.

JPMorgan projects that by 2030, the rise of GLP-1 drugs could slash annual food and drink sales by $30 billion to $55 billion. Right now, about 12% of U.S. Adults take these drugs. That figure could swell to more than 30 million people within a few years, as new pills enter the market and awareness spreads.

Snacking has taken the hardest blow. Surveys show around 70% of GLP-1 users who eat less say they’re cutting back on snacks. That’s no small matter. Snacking once drove grocery sales growth, but now companies see it as a vulnerable segment. Breakfast and other meal categories are also shifting as users skip or shrink their portions.

Food businesses pivot to survive

Some restaurant chains and packaged food makers aren’t just watching — they’re acting. They’re tweaking menus and product lines to appeal to GLP-1 users. That means smaller servings, more protein, and higher fiber content.

Protein and fiber tend to keep people feeling full longer, which fits the needs of those on these drugs.

Mastheads

Don K. Johnson of EY-Parthenon notes that brands are even marketing products as "GLP-1 friendly" to attract this new customer base. Beverage companies, for example, are focusing on hydration products, since staying hydrated is important for GLP-1 users.

Still, it’s a delicate balance. If portions shrink too much or products change too drastically, existing customers might turn away. Food firms have to find new ways to grow revenue while catering to a fundamentally different appetite landscape.

Biotech’s next frontier: making GLP-1 inside your body

Beyond pills and injections, the GLP-1 revolution has other implications. Two biotech startups, RenBio and Fractyl Health, are working on gene therapies designed to turn muscle cells into tiny factories producing GLP-1 naturally. The idea is one injection could provide long-lasting effects, potentially sidestepping some issues with current drugs.

Both companies have shown promising results in mice and are now testing in larger animals. But human trials are still years away. Successful therapies could transform obesity treatment, boosting demand for GLP-1-friendly products.

Current GLP-1 drugs help lower blood sugar and reduce appetite by mimicking the body’s own hormone. They've helped push the U.S. Obesity rate down from nearly 40% in 2023 to 37% in 2025, according to Gallup. Yet, the medications aren’t cheap, and side effects like nausea and fatigue lead many to stop using them within a year.

Economic ripple effects

GLP-1 drugs aren’t just changing diets. They’re pressuring food companies’ bottom lines and forcing a rethink of product development and marketing. The industry faces a future where consumers eat less but demand higher-quality, nutrient-dense food. That could be good news for some sectors — like protein and fiber producers — but bad for others reliant on volume and indulgence.

Investors are watching closely, as food giants scramble to adapt. The question is whether these companies can innovate fast enough to offset shrinking sales among GLP-1 users. The stakes are high; if trends persist, America's food and beverage landscape could change dramatically by decade's end.

Related Articles

As GLP-1 drugs become mainstream, the food industry faces a turning point. Will businesses successfully reinvent themselves for a leaner, more health-conscious customer? Or will the appetite for change outpace their ability to keep up?

This article was created with AI assistance.